Objective-Platelet hyperactivity is associated with vascular disease and contributes to the genesis of thrombotic disorders.
A DP released from platelets, red blood cells, and damaged blood vessels is a key activator of platelets and plays an important role in generation of arterial thrombi at the site of vascular injury. 1 Two G-protein-coupled receptors, P2Y 1 and P2Y 12 , are required for full ADP-induced platelet aggregation, but each of these receptors plays a different role in this process. 2,3 P2Y 1 receptor (P2Y 1 R) triggers a rapid and transient intracellular calcium increase that causes platelet shape change and initiates the process of platelet activation. 4-6 P2Y 12 receptor (P2Y 12 R) mediates a slower and more sustained decrease in cAMP, which amplifies and consolidates ADP-driven platelet activation. 4, 5, 7 Coactivation of both P2Y 1 R and P2Y 12 R is required for a complete platelet response; however, blockade of either receptor significantly decreases ADP-induced platelet aggregation and thrombosis. 8, 9 Among these, the P2Y 12 R is the molecular target of the antithrombotic drug clopidogrel, 10 and extensive work is in progress in many laboratories and pharmaceutical companies to provide new compounds acting at the P2Y 12 R. 11, 12 It is noteworthy that pharmacological studies and studies with P2Y 1 R-deficient mice indicate that these receptors could also be relevant targets for new antiplatelet compounds. 13 About the P2Y 1 R, studies with P2Y 1 R −/− mice indicated defective aggregation in response to ADP and low concentrations of collagen. 14, 15 These animals displayed resistance to systemic thromboembolism induced by infusion of either a mixture of collagen and adrenaline 14, 15 or tissue factor, 16 pointing to the essential role of this receptor in thrombin-dependent or thrombin-independent model of thrombosis. Moreover, in a model of localized arterial thrombosis of mesenteric arterioles triggered by ferric chloride injury, P2Y 1 R −/− mice also displayed reduced and delayed thrombus formation when compared with the wild type. 17 In this model, the extent of inhibition was found to be equivalent to that of clopidogrel-treated animals at the maximal effective dose. 17 In addition, the combination of P2Y 1 R deficiency and clopidogrel treatment was found to be more efficient than each alone, opening the possibility that a combination of P2 receptor antagonists could improve antithrombotic strategies. 17 Altogether, these results suggested the P2Y 1 R to be a potential target for new antiplatelet compounds. March 2015
To this end, the present studies characterized the biological activity of a novel antibody targeted against the ligand-binding domain of the platelet P2Y 1 R (ie, second extracellular loop [EL2]) abbreviated as EL2Ab in the context of platelet function. The EL2Ab was found to recognize the P2Y 1 R protein specifically and to inhibit aggregation of human and mouse platelets induced by ADP, in a dose-dependent manner, whereas it produced no effects on aggregation mediated by the thromboxane receptor (TPR), or in response to thrombin and collagen stimulation. Moreover, the EL2Ab also inhibited GP IIb-IIIa activation, platelet dense and α granule secretion, and phosphatidylserine exposure. Radioligand binding studies revealed that the mechanism by which EL2Ab exerts these effects involves interaction/antagonism of the P2Y 1 R. Importantly, our data provide evidence that EL2Ab does not interact with the P2Y 12 R. Considering the biological function of the P2Y 1 R, it could be hypothesized that an antibody raised against the receptor's ligand-binding domain (ie, EL2) should in turn prevent thrombosis much in the same way as an antagonist. Indeed, in vivo analysis demonstrated that although EL2Ab prolongs the time for occlusion and protects against thrombogenesis, it does so accompanied by impairing hemostasis and prolonging tail bleeding time.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

EL2Ab Recognizes the P2Y 1 R in Human and Mouse Platelets
The purpose of these studies is to provide evidence that the EL2Ab, which was generated against the EL2 region of the P2Y 1 R, does indeed have the capacity to recognize the receptor protein, in both human and mouse platelet preparations. Thus, in our initial characterization, we used Western blotting and flow cytomtery analysis of the P2Y 1 R using the EL2Ab. Consequently, our Western blot data revealed that when the EL2Ab was used as the primary antibody, it did in fact recognize the P2Y 1 R protein, with a band observed at ≈47 kDa, in both human ( Figure 1A ) and mouse platelets ( Figure 1B ). On the contrary, when the EL2Ab was first preabsorbed with its cognate peptide (EL2; 100 μmol/L) no band was observed, indicating that it was no longer capable of recognizing the P2Y 1 R protein ( Figure 1A and 1B), as would be expected, thereby supporting the specificity of this antibody. Together, these findings do indicate that the EL2Ab, which was generated against the human EL2 domain, exhibits interspecies reactivity, at least toward the mouse receptor, and under denatured protein conditions. In separate positive control studies, Western blot was conducted using a commercial anti-human P2Y 1 R antibody. The results revealed a band corresponding to the P2Y 1 R protein at 47 kDa, in both human and mouse platelets ( Figure 1A and 1B), similar to what was observed with EL2Ab under similar experimental conditions. In the next set of experiments, we investigated the capacity of the EL2Ab to recognize the native P2Y 1 R protein by using flow cytomtery analysis. It was found that incubating human and mouse platelets with the EL2Ab resulted in a significant rightward shift in the mean fluorescence intensity, when compared with the normal rabbit IgG control ( Figure 1C and 1D). Conversely, the preabsorbed EL2Ab did not produce a significant rightward shift in the mean fluorescence intensity ( Figure 1C and 1D), ie, similar to what was found with normal rabbit IgG. This finding supports the specificity of the EL2Ab and the observed response. Moreover, separate positive control studies using a commercial anti-human P2Y 1 R antibody also revealed a rightward shift in the mean fluorescence intensity in human and mouse platelets ( Figure 1C and 1D), which was comparable with what we observed with the EL2Ab. In a separate set of control experiments, EL2Ab was found to recognize the P2Y 1 R protein in the wild-type but not in the P2Y 1 R −/− platelets, further supporting the specificity of the EL2Ab ( Figure 1E ). Moreover, flow cytometric analysis revealed similar results ( Figure 1F ). Taken together, these findings clearly establish that the EL2Ab, which was raised against the human EL2 sequence, exhibits interspecies reactivity, and that it has the capacity to recognize the denatured and the native forms of the human, as well as the mouse P2Y 1 receptor protein, at least for those receptors that are known to be expressed on platelets.
Figure 2.
Second extracellular loop (EL2) of the P2Y 1 receptor (EL2Ab) inhibits platelet aggregation in vitro and ex vivo. Platelets were incubated with different concentrations of EL2Ab (3.125-12.5 ng) for 3 minutes and stimulated with either 5 μmol/L, ADP (A); 1 μmol/L, U46619 (B); 0.1 U/mL thrombin (C); or 5 μg/mL collagen (D). Each experiment was repeated 3×, with blood obtained from 3 separate donors. For the ex vivo studies, mice were injected with 12.5 ng of EL2Ab or IgG, and blood/platelets were collected 1 hour post injection. Platelets were stimulated with either 5 μmol/L, ADP (E) or 1 μmol/L, U46619 (F). Each experiment was repeated ≥3×, with blood pooled from ≥3 separate groups of 8 mice. March 2015
EL2Ab Inhibits Platelet Aggregation of Human and Murine Platelets: In Vitro
Previous work has demonstrated that EL2 of P2Y 1 R contains an important ligand-binding pocket. [18] [19] [20] [21] [22] Thus, we proposed that an antibody targeting this region (EL2Ab) would significantly block ADP-induced platelet aggregation. In our initial experiments, we showed that 6.25 ng of EL2Ab significantly inhibited human platelet aggregation induced by 5 μmol/L ADP when compared with normal rabbit IgG (Figure 2A ). Furthermore, this inhibition was found to be dose dependent (Figure 2A ). On the contrary, control experiments revealed that the EL2Ab even at 12.5 ng did not produce any detectable effects on platelet activation by the TPR agonist U46619 (1 μmol/L; Figure 2B ), thrombin (0.1 U/mL; Figure 2C ), or collagen (5 μg/mL; Figure 2D ). The specificity of this effect was further demonstrated by the loss of EL2Ab ability to inhibit aggregation after preabsorption with 100 μmol/L of its cognate peptide (data not shown). Similar results were also obtained under in vitro conditions in mouse platelets (data not shown). Together, these findings indicate that EL2Ab inhibitory effects are selective to the P2Y 1 R, but not to the TPR.
EL2Ab Inhibits Platelet GPIIb-IIIa Activation
We next investigated whether the blockade of ADP-induced platelet aggregation by EL2Ab would be associated with a commensurate inhibition of GPIIb-IIIa activation. Indeed, our results showed that pretreating platelets with 12.5 ng of EL2Ab significantly reduced 5 μmol/L ADP-triggered PAC-1 (platelet activation complex-1) binding, indicating inhibition of GPIIb-IIIa activation ( Figure 3A ). On the contrary, 12.5 ng of EL2Ab had no detectable effects on 1 μmol/L U46619/ TPR-induced GPIIb-IIIa activation ( Figure 3B ).
EL2Ab Inhibits Platelet α and Dense Granule Secretion
Platelet secretion is an important and early event in platelet activation that is known to be triggered by the agonist ADP. Thus, we sought to determine whether the EL2Ab would exert inhibitory effects on platelet secretion. It was found that 12.5 ng of EL2Ab significantly inhibited platelet α and dense granule secretion stimulated by 5 μmol/L ADP ( Figure 3C and 3E, respectively), when compared with normal rabbit IgG (not shown). Conversely, no detectable effects on dense and α granule secretion were observed when platelets were activated by U46619 (1 μmol/L; Figure 3D and 3F, respectively). These data show that EL2Ab does indeed exert inhibitory effects on dense and α granule secretion.
EL2Ab Inhibits Platelet Phosphatidylserine Exposure
Exposure of platelet membrane phosphatidylserine regulates blood coagulation by modulating the production of thrombin. We examined whether the EL2Ab interaction with the P2Y 1 R would interfere with phosphatidylserine exposure. Indeed, our studies demonstrated that pretreatment of platelets with EL2Ab (12.5 ng) significantly inhibited 5 μmol/L ADP-induced The reactions were stopped by fixing the platelets with 2% formaldehyde for 30 minutes at room temperature. A and B, Platelets were incubated with fluorescein isothiocyanate (FITC)-conjugated PAC-1 antibody, the fluorescent intensities were measured by flow cytometry, and the data were plotted as histogram. C and D, Platelets were incubated with FITC-conjugated anti-P-selectin antibody, the fluorescent intensities were measured by flow cytometry, and the data were plotted as histogram. G and H, Platelets were incubated with FITC-conjugated annexin V antibody, the fluorescent intensities were measured by flow cytometry, and the data were plotted as histogram. Platelets were incubated with EL2Ab (12.5 ng) for 3 minutes, 12.5 μL of luciferase luciferin was added and stimulated with either 5 μmol/L, ADP (E) or 1 μmol/L, U46619 (F) for 5 minutes. Release of ATP as a luminescence was measured by aggregometer. Each experiment was repeated ≥3×, with blood obtained from 3 separate donors. phosphatidylserine exposure ( Figure 3G ), whereas it exerts no effect on that stimulated by 1 μmol/L U46619 ( Figure 3H ). These data provide evidence that the mechanism by which EL2Ab inhibits platelet function involves phosphatidylserine exposure.
EL2Ab Competitively Displaces Radiolabeled [ 3 H] MRS2500 From P2Y 1 R Ligand-Binding Sites
To define the molecular mechanism by which EL2Ab blocks P2Y 1 R-mediated platelet activation, a radiolabeled ligandbinding assay was performed. Because this antibody was raised against second extracellular loop of P2Y 1 receptor, which is part of the ligand-binding pocket, it would be expected to compete with other ligands for receptor binding effectively. Thus, platelets were incubated with the radiolabeled P2Y 1 R antagonist [ 3 H]MRS2500, and increasing concentration of EL2Ab were added (1-15 ng). We observed a dose-dependent displacement of [ 3 H]MRS2500 from its P2Y 1 R ligand-binding sites by EL2Ab ( Figure 4A ); this effect was found to be reversed by preabsorption of EL2Ab with its cognate peptide ( Figure 4A ). Thus, the EL2Ab clearly binds to platelet P2Y 1 Rs in a specific manner, which is consistent with its antiplatelet effects.
EL2Ab Does Not Interact With P2Y 12 R
In platelets, the agonist ADP is known to activate 2 separate G-protein-coupled receptors, namely the P2Y 1 R, and the P2Y 12 R (known to couple to G i ). To confirm the selectivity of the EL2Ab for the P2Y 1 R, and examine whether it can inhibit P2Y 12 -dependent activity, a cAMP assay was conducted using human platelets, as we described before. [23] [24] [25] Our findings demonstrate that 5 μmol/L of ADP significantly lowered/ inhibited 0.5 μmol/L forskolin-induced increases in cAMP levels ( Figure 4B ). Furthermore, pretreatment with 12.5 ng of the EL2Ab, which almost completely inhibited the aggregation response, did not produce any apparent effects on the ability of ADP (5 μmol/L) to lower cAMP levels that were elevated by 0.5 μmol/L of forskolin ( Figure 4B ), unlike 1 μmol/L of the P2Y 12 R antagonist AR-C 66096 ( Figure 4B ). Thus, these data provide evidence that the inhibitory effects the EL2Ab exerts on platelets are exclusively dependent on its interaction with the P2Y 1 R.
EL2Ab Inhibits Murine Platelet Aggregation: Ex Vivo
Our initial experiments showed that EL2Ab inhibits ADPinduced platelet aggregation in human and in mouse platelets under in vitro experimental conditions. Thus, to examine a potential antithrombotic activity for EL2Ab better, and to guide the selection of doses for our in vivo studies, we decided to examine whether injections into live animals would also translate into inhibition of platelet aggregation. Indeed, it was found that 1 hour post tail-vein injections of 12.5 ng of EL2Ab administered intravenously into mice produced significant inhibition of ADP-stimulated aggregation (5 μmol/L; Figure 2E ), whereas no effects were observed with the TPR agonist U46619 (1 μmol/L; Figure 2F ). Hence, these data suggest that EL2Ab does have the capacity to inhibit platelet function even when injected into live animals.
EL2Ab Inhibits Thrombogenesis and Hemostasis
Because actin-dependent myosin contractility is thought to contribute to thrombus stability in the arterial system, 26 we sought to assess the pharmacological relevance of the EL2Ab in vivo, by conducting a murine FeCl 3 carotid artery injury thrombosis experiments. We found that the EL2Ab-treated animals (12.5 ng IV injections) had a prolonged time for occlusion ( Figure 5A ), when compared with normal rabbit IgG ( Figure 5A ). Furthermore, this prolongation was comparable with that observed with the experimental P2Y 1 R antagonist MRS2500 (2 mg/kg; Figure 5A ). We next investigated whether the EL2Ab would exert negative consequences on hemostasis by measuring the tail bleeding times. It was found that mice injected with 12.5 ng EL2Ab significantly prolonged tail bleeding times when compared with control animals ( Figure 5B ), when compared with IgG control ( Figure 5B) . Again, the P2Y 1 R MRS2500 exerted similar effects on the tail bleeding time ( Figure 5B ). Taken together, the above data provide evidence that the EL2Ab not only exhibits antithrombotic activity but also increases the risk of bleeding.
Discussion
Whereas platelet activation is an integral part of hemostasis, vessel disease and vascular lesions are also major causative factors in arterial thrombosis. Thus, agents that interfere with the activation of platelets by their agonists have traditionally served as potential candidates for antithrombotic therapy. 27, 28 For example, drugs that target ADP-signaling pathways for pharmacological inhibition have been promoted as logical therapeutic approaches because of the presumed importance of secreted ADP in propagating the platelet aggregation response induced by numerous agonists. [29] [30] [31] [32] Of the 2 ADP-receptor signaling pathways in platelets, evidence has indicated that ADP-mediated P2Y 12 signaling seems to play a more prominent role in platelet activation than the P2Y 1 pathway. 33, 34 For the most part, support for this notion derives from the use of P2Y 12 antagonists 35 which, unlike P2Y 1 antagonists, 14 substantially inhibit aggregation to many platelet agonists, including thromboxane A 2 , thrombin, and collagen. [36] [37] [38] However, there is an accumulating evidence that this potent biological activity is the underlying cause for the significant bleeding phenotype associated with the use of P2Y 12 antagonists (eg, ticlopidine and clopidogrel; Plavix), which may limit their clinical utility. Thus, it is reasonable to suggest that a less-potent inhibitor (with a narrower spectrum of activity) may serve as a safer alternative. Consequently, antagonism of the P2Y 1 receptor, which was established using transgenic 14, 15, 17 and pharmacological approaches 17,39-42 as a mediator in thrombotic disease, 14,15,17,39,41-43 has re-emerged as an alternative approach for targeting the ADP pathway and for managing such disease states. In fact, historically, the P2Y 1 R is the one thought to be responsible for the initiation of aggregation in response to ADP, but not the receptor that is targeted by clopidogrel (ie, the P2Y 12 receptor). 44 It is noteworthy that despite an apparent success with the design of small-molecule P2Y 1 R antagonists, unfortunately, each seemed to exhibit a certain handicapping deficiency (ie, limitations ranged from limited in vivo effectiveness, short biological half-life, toxicity, to poor potency, as well as oral bioavailability issues). One apparent reason for these failures is because these agents were empirically designed based on the structures of ADP or ATP, with little information about the actual P2Y 1 R binding domains. On the basis of these considerations, we assumed that pharmacological inhibition of the P2Y 1 R with the current agents may not efficiently and reliably inhibit thrombosis in vivo. In our effort to design anti-P2Y 1 R agents, we hypothesized that an antibody targeting the ligand-binding site within the EL2 of the ADP/P2Y 1 R (ie, amino acids T 192 -F 215 ) can be used as a function-blocking reagent for platelet activation. This hypothesis is based on the notion that the EL2 domain of the P2Y 1 R plays an important role in ADP-induced platelet activation. Consequently, the aim of the present study was to characterize the antiplatelet and antithrombotic properties of this novel, custom-made antibody targeted against the EL2Ab. Our study should also provide insight into the pharmacological and potential therapeutic relevance of EL2Ab, and perhaps further validate the concept that targeting the P2Y 1 R remains a relevant and viable alternative or complement to other antiplatelet strategies.
Our initial characterization revealed that EL2Ab has the capacity to recognize the denatured and native forms of the P2Y 1 R protein, in a specific manner (eg, no band was detected in the P2Y 1 −/− platelets). So, we next sought to examine the antiplatelet activity of EL2Ab in both human and murine platelets/models. Our results indicated that EL2Ab dose dependently inhibited ADP/P2Y 1 R-mediated platelet aggregation, in human (in vitro) and in mouse platelets (in vitro and ex vivo), and that this inhibition was found to be commensurate with its blockade of GPIIb-IIIa activation. These results also established EL2Ab as the first function-blocking antibody against ADP P2Y 1 R. Moreover, the dose-response profiles, coupled with the Western blot and flow cytometry analysis, indicate that there are no species (human versus mouse) differences in the EL2Ab affinity/potency for inhibiting aggregation induced by ADP, at least under in vitro conditions. This is not surprising given that the mouse and human P2Y 1 Rs are identical in 20 of the 24 amino acids of EL2.
We also found that EL2Ab inhibited separate in vitro platelet functional responses, namely dense and α granule secretion, as well as phosphatidylserine exposure. Given that these responses are also mediated via the P2Y 12 R, we assessed whether EL2Ab may cross react with its receptor protein. However, our data argue against this possibility as evidenced by the lack of ability of EL2Ab to interfere ADPinduced reduction in forskolin-mediated increases in cAMP, unlike the P2Y 12 R antagonist AR-C 66096. To investigate the mechanism of action of EL2Ab further, radioligand displacement binding studies were performed using a selective P2Y 1 R antagonist. Our data showed that EL2Ab displaced [ 3 H]MRS2500 from its P2Y 1 R, unlike its preabsorbed form. These data clearly demonstrate that EL2Ab exerts its inhibitory effects by directly binding to P2Y 1 R ligand-binding site, thereby inhibiting ADP from binding to and activating the receptor protein.
Finally, having established the capacity of EL2Ab to inhibit platelet function (in vitro and ex vivo), we next determined whether these effects would uphold under in vivo experimental models (eg, antithrombotic activity). Indeed, our data in the murine model indicated that, similar to the experimental P2Y 1 R antagonist MRS2500, EL2Ab was found to prolong the time for thrombus occlusion, supporting its use as antithrombotic agent. However, EL2Ab was also found to prolong the tail bleeding time, in mice, indicating that it also impairs hemostasis, much like MRS2500.
Collectively, these findings support the notion that antibody interaction with the EL2 region specifically blocks aggregation mediated through the ADP/P2Y 1 R pathway and that the P2Y 1 R remains a relevant clinical target, as an alternative or a complement to current therapeutically used antiplatelet strategies. Because an Ab-based antiplatelet biological has previously been approved by the Food And Drug Administration (ie, the GPIIb-IIIa antagonist abciximab/ReoPro), it is possible that EL2Ab would also have clinical applications, alone or in combination with other antithrombotic agents, especially given the limitations of the commonly used thromboembolic therapy (eg, resistance and severe bleeding associated with aspirin or Plavix). Finally, the identification of a functionally active P2Y 1 R sequence, ie, EL2, should significantly aid molecular modeling study predictions for organic derivatives, which possess in vivo activity. This is an important consideration because in spite of the clear involvement of P2Y 1 R signaling in occlusive vascular disease, P2Y 12 antagonists are still the only clinically effective drugs for the prevention of ADP-induced platelet activation.
These studies, some of which are translational in nature, address fundamental questions about the platelet P2Y 1 receptor structure, signaling, and function. These studies also constitute the first investigation of antibody-based inhibition of P2Y 1 receptor function in platelets and highlight its EL2 domain as a potential target site for therapeutic interventions. Results obtained from these studies should provide knowledge and lay down the foundation for defining new and novel therapeutic targets or agents for the therapeutic management of multiple thrombosisbased disease states. Thus, EL2Ab could have widespread (experimental and) therapeutic applications, perhaps even as a complement or alternative in combination therapies.
Significance
